Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
1.61% $20.17
America/New_York / 23 apr 2024 @ 12:24
FUNDAMENTALS | |
---|---|
MarketCap: | 1 514.12 mill |
EPS: | -1.020 |
P/E: | -19.77 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 75.07 mill |
Avg Daily Volume: | 0.666 mill |
RATING 2024-04-23 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -19.77 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.36x |
Company: PE -19.77 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-5.12 (-125.38%) $-25.29 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 19.30 - 21.12 ( +/- 4.52%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Eastham Karin | Buy | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Stock Option (right to buy) |
2024-03-15 | Chambers Rebecca | Buy | 4 318 | Common Stock |
2024-03-15 | Chambers Rebecca | Sell | 2 189 | Common Stock |
INSIDER POWER |
---|
32.48 |
Last 99 transactions |
Buy: 1 146 076 | Sell: 688 515 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $20.17 (1.61% ) |
Volume | 0.199 mill |
Avg. Vol. | 0.666 mill |
% of Avg. Vol | 29.86 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.03 | N/A | Active |
---|
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.